Journey Medical (NASDAQ:DERM) reported Q3 2023 earnings of $0.99 per share, beating the analyst consensus estimate of $(0.15) by 760 percent. This is a 530.43 percent increase over losses of $(0.23) per share from the same period last year. The company also reported quarterly sales of $34.54 million, beating the analyst consensus estimate of $16.88 million by 104.61 percent, a 114.31 percent increase over sales of $16.12 million the same period last year.